These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 4729733

  • 21. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive.
    Spellacy WN, Kalra PS, Buhi WC, Birk SA.
    Am J Obstet Gynecol; 1980 May 01; 137(1):109-15. PubMed ID: 6768295
    [Abstract] [Full Text] [Related]

  • 22. Norethisterone enanthate as an injectable contraceptive in puerperal and non-puerperal women.
    Melis GB, Strigini F, Fruzzetti F, Paoletti AM, Rainer E, Düsterberg B, Fioretti P.
    Contraception; 1981 Jan 01; 23(1):77-88. PubMed ID: 6781816
    [Abstract] [Full Text] [Related]

  • 23. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov 01; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A, Faure N, Labrie F, Fazekas AT.
    Fertil Steril; 1985 Jun 01; 43(6):868-77. PubMed ID: 3158551
    [Abstract] [Full Text] [Related]

  • 25. The effect of ovarian steroid feedback upon radioimmunoreactive luteinizing hormone releasing hormone in the hypothalamus.
    Yanaihara T, Arai K, Kanazawa M, Okinaga S, Yanaihara N, Yanaihara C.
    Endocrinol Jpn; 1975 Dec 01; 22(6):525-30. PubMed ID: 782859
    [Abstract] [Full Text] [Related]

  • 26. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC, Jouannet P, Marson J, Soumah A.
    Acta Endocrinol (Copenh); 1983 Apr 01; 102(4):625-32. PubMed ID: 6221496
    [Abstract] [Full Text] [Related]

  • 27. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M, Nicol K, Petersen IB, Schou G.
    Contraception; 1980 Jun 01; 21(6):631-40. PubMed ID: 6775869
    [Abstract] [Full Text] [Related]

  • 28. Plasma profile on pituitary gonadotropins and ovarian steroids in women during 17 alpha-acetoxy- 11 beta-methyl-19-nor-progesterone administration.
    Pérez-Palacios G, Iramain C, Castañeda E, Rojo B, Long DW, Scaglia HE, Gual C.
    Contraception; 1975 Jul 01; 12(1):37-43. PubMed ID: 1139948
    [Abstract] [Full Text] [Related]

  • 29. The effect of oestrogen administration on plasma testosterone, FSH and LH levels in patients with Klinefelter's syndrome and normal men.
    Smals AG, Kloppenborg PW, Lequin RM, Benraad TJ.
    Acta Endocrinol (Copenh); 1974 Dec 01; 77(4):765-83. PubMed ID: 4479709
    [Abstract] [Full Text] [Related]

  • 30. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K, Lunell NO, Zador G.
    Gynecol Obstet Invest; 1978 Dec 01; 9(6):304-11. PubMed ID: 754992
    [Abstract] [Full Text] [Related]

  • 31. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
    Laumas V, Jain AK, Jha P, Rahman SA, Kumar D, Malik BK, Sarkar NN, Takkar D, Hingorani V, Laumas KR.
    Contraception; 1981 Feb 01; 23(2):211-25. PubMed ID: 6786828
    [Abstract] [Full Text] [Related]

  • 32. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
    Song S, Chen JK, Lu CH, Yang PJ, Yang QY, Fan BC, He ML, Gui YL, Li LM, Fotherby K.
    Contraception; 1993 Jun 01; 47(6):527-37. PubMed ID: 8334889
    [Abstract] [Full Text] [Related]

  • 33. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan 01; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 34. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
    Porcile A, Gallardo E.
    Fertil Steril; 1991 May 01; 55(5):877-81. PubMed ID: 1827074
    [Abstract] [Full Text] [Related]

  • 35. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P.
    Fertil Steril; 1990 Apr 01; 53(4):747-50. PubMed ID: 2108063
    [Abstract] [Full Text] [Related]

  • 36. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
    Carr BR, Parker CR, Madden JD, MacDonald PC, Porter JC.
    J Clin Endocrinol Metab; 1979 Sep 01; 49(3):346-9. PubMed ID: 224073
    [Abstract] [Full Text] [Related]

  • 37. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
    Robyn C, Vekemans M.
    Acta Endocrinol (Copenh); 1976 Sep 01; 83(1):9-14. PubMed ID: 989226
    [Abstract] [Full Text] [Related]

  • 38. On the mechanism of action of progestins.
    Pérez-Palacios G, Fernández-Aparicio MA, Medina M, Zacarías-Villareal J, Ulloa-Aguirre A.
    Acta Endocrinol (Copenh); 1981 Jul 01; 97(3):320-8. PubMed ID: 6455041
    [No Abstract] [Full Text] [Related]

  • 39. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
    Berga SL, Yen SS.
    Clin Endocrinol (Oxf); 1989 Feb 01; 30(2):177-84. PubMed ID: 2532984
    [Abstract] [Full Text] [Related]

  • 40. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.
    Givens JR, Andersen RN, Wiser WL, Fish SA.
    J Clin Endocrinol Metab; 1974 May 01; 38(5):727-35. PubMed ID: 4823918
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.